J&J, Pfizer Profit on `Juvenile Bipolar Juggernaut' (Update2)Bloomberg - Sep 5, 2007The expanded use of bipolar disorder as a pediatric diagnosis has made children the fastest-growing part of the $11.5 billion US market for antipsychotic …

Read full story